Benitec Biopharma Ltd Company Profile (NASDAQ:BNTC)

Analyst Ratings

Consensus Ratings for Benitec Biopharma Ltd (NASDAQ:BNTC) (?)
Ratings Breakdown: 1 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $14.00 (709.25% upside)

Analysts' Ratings History for Benitec Biopharma Ltd (NASDAQ:BNTC)
Show:
DateFirmActionRatingPrice TargetActions
2/26/2016Maxim GroupDowngradeBuy -> Hold$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Benitec Biopharma Ltd (NASDAQ:BNTC)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Benitec Biopharma Ltd (NASDAQ:BNTC)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Benitec Biopharma Ltd (NASDAQ:BNTC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Benitec Biopharma Ltd (NASDAQ:BNTC)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Benitec Biopharma Ltd (NASDAQ:BNTC)
DateHeadline
05/25/16 12:23 PMBenitec Biopharma Interim Report for the Nine Months Ended March 31, 2016 - PR Newswire (press release) - Benitec Biopharma Interim Report for the Nine Months Ended March 31, 2016PR Newswire (press release)SYDNEY, May 24, 2016 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today lodged its Interim Report for the nine months ended March 31, 2016. The report includes the financial results and a review of ...and more »
05/25/16 12:23 PMBenitec Biopharma : QUARTERLY REPORT CONFERENCE CALL TRANSCRIPT - Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today lodged its transcript for the conference call taking place at 8.00am AEST on 25 May, 2016. Good morning everyone. The purpose of today's call is to provide an update in line with our ...
05/24/16 05:36 PMQUARTERLY REPORT CONFERENCE CALL TRANSCRIPT - [at noodls] - 14fa0040-ec16-4dc8-9a84-64f3f1298167.pdf ASX ANNOUNCEMENT Benitec Biopharma Quarterly Report Conference Call Transcript Sydney Australia, 25 May 2016: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; ...
05/24/16 03:45 AMBenitec Biopharma Interim Report for the Nine Months Ended March 31, 2016 - [PR Newswire] - SYDNEY, May 24, 2016 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today lodged its Interim Report for the nine months ended March 31, 2016. The report includes the ...
05/24/16 02:56 AMINTERIM REPORT NINE MONTHS TO 31 MARCH 2016 - [at noodls] - 51d1ced1-c9dc-46cd-a23f-628dd49f0d58.pdf ASX/NASDAQ ANNOUNCEMENT Interim Report for the Nine Months Ended March 31, 2016 Sydney, Australia -­‐ May 24, 2016 -­‐ Benitec Biopharma Limited (ASX: BLT; NASDAQ: ...
05/17/16 12:34 PMBenitec Biopharma to Host Corporate Update Conference Call - PR Newswire (press release) - Benitec Biopharma to Host Corporate Update Conference CallPR Newswire (press release)SYDNEY, May 17, 2016 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced that the Company will host a conference call and live audio webcast on Wednesday, 25 May 2016 at 8:00am AEST ...and more »
05/17/16 04:02 AMQUARTERLY CORPORATE UPDATE CONFERENCE CALL - [Other] - 1494fe53-7ab8-416d-83f1-9f7222382504.pdf ASX/NASDAQ ANNOUNCEMENT Benitec Biopharma to Host Corporate Update Conference Call Conference Call and Live Audio Webcast Scheduled for Wednesday, 25 May 2016 at ...
05/06/16 12:24 PMTop Stories: Benitec Biopharma Limited (NASDAQ:BNTC), Heron Therapeutics, Inc. (NASDAQ:HRTX), Altra Industrial ... - KC Register - Top Stories: Benitec Biopharma Limited (NASDAQ:BNTC), Heron Therapeutics, Inc. (NASDAQ:HRTX), Altra Industrial ...KC RegisterBenitec Biopharma Limited (NASDAQ:BNTC) announced acceptance of five presentations at the 19th Annual Meeting of American Society of Gene and Cell Therapy (ASGCT) being held in Washington D.C. on May 4-7, 2016. On Thursday Benitec Biopharma ...and more »
05/05/16 12:06 PMBenitec Biopharma Limited Ads (NASDAQ:BNTC) Shorted Shares Increased 138.36% After Market Selling - B.O.D.Y Confidential - Benitec Biopharma Limited Ads (NASDAQ:BNTC) Shorted Shares Increased 138.36% After Market SellingB.O.D.Y ConfidentialThe stock of Benitec Biopharma Limited Ads (NASDAQ:BNTC) registered an increase of 138.36% in short interest. BNTC's total short interest was 17,400 shares in May as published by FINRA. Its up 138.36% from 7,300 shares, reported previously. With 6,700 ...
05/04/16 11:32 AMWhy Need to Watch: Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Benitec Biopharma Limited (NASDAQ:BNTC), First ... - KC Register - Why Need to Watch: Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Benitec Biopharma Limited (NASDAQ:BNTC), First ...KC RegisterBenitec Biopharma Limited (NASDAQ:BNTC) traded 50726 shares and its share price moved up 1.79% to close at $1.71. Benitec Biopharma Limited (NASDAQ:BNTC) quarterly performance is -51.14% while its year to date (YTD) performance is -57.46%.
05/03/16 11:34 AMStocks to Watch: Heat Biologics, (NASDAQ:HTBX), Benitec Biopharma (NASDAQ:BNTC), Globus Maritime (NASDAQ ... - KC Register - Stocks to Watch: Heat Biologics, (NASDAQ:HTBX), Benitec Biopharma (NASDAQ:BNTC), Globus Maritime (NASDAQ ...KC RegisterBenitec Biopharma Limited (NASDAQ:BNTC) traded 56288 shares and its share price increased 13.51% to close at $1.68. Benitec Biopharma Limited (NASDAQ:BNTC) quarterly performance is -52.53% while its year to date (YTD) performance is -58.21%.
05/03/16 11:34 AMStock Highlights: Benitec Biopharma (NASDAQ:BNTC), Genocea Biosciences, (NASDAQ:GNCA), First American ... - KC Register - Stock Highlights: Benitec Biopharma (NASDAQ:BNTC), Genocea Biosciences, (NASDAQ:GNCA), First American ...KC RegisterBenitec Biopharma Limited (NASDAQ:BNTC) announced acceptance of five presentations at the 19th Annual Meeting of American Society of Gene and Cell Therapy (ASGCT) being held in Washington D.C. on May 4-7, 2016. The abstracts cover the scientific ...
04/25/16 12:05 PMBenitec to present at the ASGCT 2016 Annual Meeting - PR Newswire (press release) - Benitec to present at the ASGCT 2016 Annual MeetingPR Newswire (press release)SYDNEY, April 25, 2016 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW), a biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or ...
04/25/16 07:30 AMBenitec to present at the ASGCT 2016 Annual Meeting - [PR Newswire] - SYDNEY, April 25, 2016 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW), a biotechnology company developing innovative therapeutics based on its patented gene-silencing ...
04/21/16 12:03 PMBenitec Biopharma : TO PRESENT AT ASGCT - Sydney Australia, April 21 2016: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW), a biotechnology company developing innovative therapeutics based on its patented gene-­‐ silencing technology called ddRNAi or 'expressed RNAi', today ...
04/20/16 11:32 PMBENITEC TO PRESENT AT ASGCT - [at noodls] - bb77e29a-4f90-4926-8727-209412f9a9e2.pdf ASX ANNOUNCEMENT Benitec to present at the ASGCT 2016 Annual Meeting Sydney Australia, April 21 2016: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: ...
04/07/16 11:57 AMBenitec Biopharma Limited Ads (NASDAQ:BNTC) Shorted Shares Increased 117.19% After Market Selling - Business Standard Tribune - Benitec Biopharma Limited Ads (NASDAQ:BNTC) Shorted Shares Increased 117.19% After Market SellingBusiness Standard TribuneThe stock of Benitec Biopharma Limited Ads (NASDAQ:BNTC) registered an increase of 117.19% in short interest. BNTC's total short interest was 13,900 shares in April as published by FINRA. Its up 117.19% from 6,400 shares, reported previously.
04/02/16 11:14 AMBenitec Biopharma Limited Ads (NASDAQ:BNTC) Short Interest Increased By 117.19% - RiversideGazette.com - Benitec Biopharma Limited Ads (NASDAQ:BNTC) Short Interest Increased By 117.19%RiversideGazette.comThe stock of Benitec Biopharma Limited Ads (NASDAQ:BNTC) registered an increase of 117.19% in short interest. BNTC's total short interest was 13,900 shares in April as published by FINRA. Its up 117.19% from 6,400 shares, reported previously.
03/29/16 11:04 AMBenitec Biopharma Limited Ads (NASDAQ:BNTC) Short Interest Increased By 117.19% - Business Standard Tribune - Benitec Biopharma Limited Ads (NASDAQ:BNTC) Short Interest Increased By 117.19%Business Standard TribuneThe stock of Benitec Biopharma Limited Ads (NASDAQ:BNTC) registered an increase of 117.19% in short interest. BNTC's total short interest was 13,900 shares in March as published by FINRA. Its up 117.19% from 6,400 shares, reported previously.
03/19/16 10:27 AMBenitec Biopharma Limited Ads (NASDAQ:BNTC) Short Interest Decreased By 3.03% - Stock Caller - Benitec Biopharma Limited Ads (NASDAQ:BNTC) Short Interest Decreased By 3.03%Stock CallerThe stock of Benitec Biopharma Limited Ads (NASDAQ:BNTC) registered a decrease of 3.03% in short interest. BNTC's total short interest was 6,400 shares in March as published by FINRA. Its down 3.03% from 6,600 shares, reported previously. With 8,200 ...
03/17/16 10:40 AMBenitec Biopharma : PRESENTS AT CANARY BIOTECH INVESTOR FORUM - Sydney, Australia, 17 March 2016: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW), a clinical-­‐stage biotechnology company developing innovative therapeutics based on its gene silencing technology, DNA-­‐directed RNA interference ...
03/09/16 10:14 AMBiotech Bulls: Omeros Corporation (NASDAQ:OMER), Xencor, Inc. (NASDAQ:XNCR), Editas Medicine Inc. (NASDAQ ... - KC Register - Biotech Bulls: Omeros Corporation (NASDAQ:OMER), Xencor, Inc. (NASDAQ:XNCR), Editas Medicine Inc. (NASDAQ ...KC RegisterBenitec Biopharma Limited (NASDAQ:BNTC) is pleased to announce that BB-HB-331, a DNA-directed RNA interference (ddRNAi) therapy targeting the hepatitis B virus (HBV), demonstrates robust and durable suppression of HBV in vivo following a single ...and more »
03/09/16 10:14 AMBenitec Biopharma Ltd (ADR) (NASDAQ:BNTC)'s Company Shares Decreased 52.38% After Low Volatility - Stock Caller - Proactive Investors AustraliaBenitec Biopharma Ltd (ADR) (NASDAQ:BNTC)'s Company Shares Decreased 52.38% After Low VolatilityStock CallerThe shares of Benitec Biopharma Ltd (ADR) (NASDAQ:BNTC) decreased by 52.38% in the last 20 days but rose 12.58% in the past 5 trading sessions. Benitec Biopharma Ltd (ADR) (NASDAQ:BNTC) shares opened at $1.73 in the last session and had ...Benitec Biopharma ADRs Jump 25% as Hepatitis B Therapy Reduces HBV DNA by 98.5% In Vivo (NASDAQ:BNTC)Sonoran Weekly ReviewBenitec Biopharma Ltd has Hepatitis B success with treatmentProactive Investors AustraliaBenitec's Hepatitis B Therapy Reduces HBV DNA by 98.5% In VivoPR Newswire (press release)all 7 news articles »
03/08/16 10:10 AMHottest Manufacturing Stocks Now - BNTC SUNE XNCR THO - Investorplace.com - Hottest Manufacturing Stocks Now - BNTC SUNE XNCR THOInvestorplace.comBenitec Biopharma Ltd. (BNTC): BNTC stock is up 14.71% today. Sunedison Inc (SUNE): SUNE stock is up 21.05% today. Xencor Inc (XNCR): XNCR stock is up 8.25% today. Thor Industries (THO): THO stock is up 8.31% today. Sucampo Pharmaceuticals ...
03/08/16 10:10 AMBenitec Biopharma Ltd has Hepatitis B success with treatment - Proactive Investors Australia - Proactive Investors AustraliaBenitec Biopharma Ltd has Hepatitis B success with treatmentProactive Investors AustraliaBenitec Biopharma Ltd (ASX:BLT; NASDAQ:BNTC) should gain a boost today as its Hepatitis B therapy has been seen to reduce the virus (HBV) by 98.5% in a mice study. The in vivo study assessed the activity of BB-HB-331 treatment in the PhoenixBio (PXB) ...Benitec's Hepatitis B Therapy Reduces HBV DNA by 98.5% In VivoPR Newswire (press release)all 4 news articles »
03/08/16 10:09 AMBenitec Biopharma Ltd has Hepatitis B success with treatment - Benitec Biopharma Ltd (ASX:BLT; NASDAQ:BNTC) should gain a boost today as its Hepatitis B therapy has been seen to reduce the virus (HBV) by 98.5% in a mice study. The in vivo study assessed the activity of BB-HB-331 treatment in the PhoenixBio (PXB ...
03/08/16 07:16 AMBenitec's Hepatitis B Therapy Reduces HBV DNA by 98.5% In Vivo - [PR Newswire] - SYDNEY, March 8, 2016 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is pleased to announce that BB-HB-331, a DNA-directed RNA interference (ddRNAi) therapy targeting ...
03/07/16 01:29 PMBenitec Biopharma Ltd. :BNTC-US: Earnings Analysis: For the six months ended December 31, 2015 -
03/03/16 10:08 AMBenitec Biopharma Limited Ads (NASDAQ:BNTC) Sellers Increased By 4.76% Their Shorts - Business Standard Tribune - Benitec Biopharma Limited Ads (NASDAQ:BNTC) Sellers Increased By 4.76% Their ShortsBusiness Standard TribuneThe stock of Benitec Biopharma Limited Ads (NASDAQ:BNTC) registered an increase of 4.76% in short interest. BNTC's total short interest was 6,600 shares in March as published by FINRA. Its up 4.76% from 6,300 shares, reported previously. With 1,400 ...
03/01/16 09:48 AMWhy Benitec Biopharma Ltd (ADR) (BNTC) got downgraded? - CWRU Observer - CWRU ObserverWhy Benitec Biopharma Ltd (ADR) (BNTC) got downgraded?CWRU ObserverBenitec Biopharma Ltd (ADR)(NASDAQ:BNTC) received a stock rating Downgrade from Maxim Group on Friday. In a note to investors, the firm issued a Hold rating. The analysts previously had an Buy rating on the stock. Analysts have a consensus target ...
02/29/16 09:52 AMWhy Benitec Biopharma Limited (ADR) (BNTC) got downgraded? - CWRU Observer - CWRU ObserverWhy Benitec Biopharma Limited (ADR) (BNTC) got downgraded?CWRU ObserverBenitec Biopharma Ltd (ADR)(NASDAQ:BNTC) received a stock rating Downgrade from Maxim Group on Friday. In a note to investors, the firm issued a Hold rating. The analysts previously had an Buy rating on the stock. Analysts have a consensus target ...Morning Alert: Benitec Biopharma Limited (NASDAQ:BNTC), Third Point Reinsurance Ltd. (NYSE:TPRE), International ...KC Registerall 2 news articles »
02/27/16 09:42 AMLos índices de Estados Unidos, mixtos al cierre; el Dow Jones Industrial Average cae un 0,34% - Investing.com España - Investing.com EspañaLos índices de Estados Unidos, mixtos al cierre; el Dow Jones Industrial Average cae un 0,34%Investing.com EspañaLe acompañaron en la parte más baja de la tabla Peregrine Pharmaceuticals Inc (O:PPHM), con un descenso del 62,26%, que se despidió en 0,4038, así como Benitec Biopharma Ltd (O:BNTC), que restó un 55,43% para despedirse en 1,5600 al término de ...and more »
02/27/16 09:42 AMHealth Care Sector Update for 02/26/2016: BNTC,KND,INOV - Nasdaq - Health Care Sector Update for 02/26/2016: BNTC,KND,INOVNasdaqIn company news, Benitec Biopharma Ltd ( BNTC ) plunged to a record low on Friday after the company said it plans to wind-down its hepatitis C program after patients in the fourth cohort of the Phase I/II trial complete their testing, explaining ...and more »
02/26/16 09:53 AMAnalysts Offer Insights on Healthcare Companies: Clovis Oncology Inc (NASDAQ: CLVS) and Benitec Biopharma Ltd ... - Markets.co - Analysts Offer Insights on Healthcare Companies: Clovis Oncology Inc (NASDAQ: CLVS) and Benitec Biopharma Ltd ...Markets.coMaxim Group analyst Jason Kolbert downgraded Benitec Biopharma (NASDAQ: BNTC) to Hold today. The company's shares closed yesterday at $3.50. Benitec Biopharma has an analyst consensus of Hold. According to TipRanks.com, Kolbert is ranked 0 ...and more »
02/26/16 09:53 AMBenitec Biopharma : UPDATE ON HCV CLINICAL TRIAL - Benitec Biopharma (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) announced today that it will wind-­‐down its hepatitis C program and terminate it upon completion of patients in Cohort 4 in its Phase I/IIa clinical trial for TT-­‐034. Benitec's Board made ...
02/26/16 06:26 AMBenitec Biopharma downgraded by Maxim Group -
02/25/16 09:13 PMBenitec Biopharma Limited: Interim Report for the Half Year Ended December 31, 2015 - [PR Newswire] - SYDNEY, Feb. 26, 2016 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today lodged its Interim Report for the half year ended December 31, 2015. The report includes Appendix ...
02/25/16 05:52 PM6:52 pm Benitec Biopharma to wind-down its hepatitis C program -
02/25/16 05:42 PMUpdate on TT-034 Hepatitis C Clinical Trial - [PR Newswire] - NASDAQ: BNTCW) announced today that it will wind-down its hepatitis C program and terminate it upon completion of patients in Cohort 4 in its Phase I/IIa clinical trial for TT-034. Benitec's Board made the decision to discontinue the hepatitis C program following a review of the commercial opportunities for TT-034. A number of effective therapies have become available for the treatment of hepatitis C since Benitec commenced its clinical trial in January 2014.
02/20/16 09:38 AMBenitec Biopharma Limited Ads (NASDAQ:BNTC) Short Interest Increased By 3.28% - Clinton Financial - Benitec Biopharma Limited Ads (NASDAQ:BNTC) Short Interest Increased By 3.28%Clinton FinancialThe stock of Benitec Biopharma Limited Ads (NASDAQ:BNTC) registered an increase of 3.28% in short interest. BNTC's total short interest was 6,300 shares in February as published by FINRA. Its up 3.28% from 6,100 shares, reported previously. With 12,300 ...
02/13/16 09:32 AMBenitec Biopharma Limited Ads (NASDAQ:BNTC) Shorted Shares Increased 3.28% After Market Selling - fdanewsalert.com - Benitec Biopharma Limited Ads (NASDAQ:BNTC) Shorted Shares Increased 3.28% After Market Sellingfdanewsalert.comThe stock of Benitec Biopharma Limited Ads (NASDAQ:BNTC) registered an increase of 3.28% in short interest. BNTC's total short interest was 6,300 shares in February as published by FINRA. Its up 3.28% from 6,100 shares, reported previously. With 12,300 ...
02/10/16 09:28 AMBenitec Biopharma Limited Ads (NASDAQ:BNTC) Shorted Shares Increased By 27.08% - fdanewsalert.com - Benitec Biopharma Limited Ads (NASDAQ:BNTC) Shorted Shares Increased By 27.08%fdanewsalert.comThe stock of Benitec Biopharma Limited Ads (NASDAQ:BNTC) registered an increase of 27.08% in short interest. BNTC's total short interest was 6,100 shares in February as published by FINRA. Its up 27.08% from 4,800 shares, reported previously.Benitec Biopharma's (BNTC) Lock-Up Period Will End on February 15thFinancial Market Newsall 2 news articles »
01/23/16 08:46 AMBenitec Biopharma Limited (BNTC) - Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing technology, DNA-directed RNA interference (ddRNAi) in Australia. Its in-house development programs include ...
12/23/15 11:37 PMFinal Director's Interest Notice - [at noodls] - 63757d36-bc4b-4872-8cea-9e299c70f474.pdf Appendix 3Z Appendix 3Z Rule 3.19A.3 Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX ...
12/09/15 07:32 AMBENITEC CFO APPOINTED INTERIM CEO - [Other] - 15bcf97b-d736-4bdc-bc9a-d473d9b39f36.pdf ASX ANNOUNCEMENT Greg West, Benitec's Chief Financial Officer and Company Secretary, Appointed Interim Chief Executive Officer Benitec's Chief Executive Officer, ...
12/09/15 07:32 AMHEP B PRECLINICAL RESULTS - [Other] - dbf054cc-6023-45ae-b42b-69e425b6bc16.pdf ASX ANNOUNCEMENT BENITEC'S HEPATITIS B THERAPEUTIC SHOWS POSITIVE PRECLINICAL RESULTS Sydney Australia, 07 December 2015: Benitec Biopharma Limited (ASX: BLT; NASDAQ: ...
12/08/15 04:05 PMGreg West, Benitec's Chief Financial Officer and Company Secretary, Named Interim Chief Executive Officer - [PR Newswire] - SYDNEY, Dec. 8, 2015 /PRNewswire/ -- The Board of Directors of Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) has today announced that Dr. Peter French will step down as Chief Executive ...
12/08/15 12:18 PMBENITEC BIOPHARMA LTD/ADR Financials -
12/07/15 07:00 AMBenitec's Hepatitis B Therapeutic Shows Positive Preclinical Results - [PR Newswire] - SYDNEY, Dec. 7, 2015 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC) is pleased to announce that initial in vitro data demonstrates efficacy of BB-HB-331, a DNA directed RNA interference ...
10/22/15 07:00 AMBenitec Biopharma's Abstract Accepted for Presentation at the AASLD Liver Meeting 2015 - [PR Newswire] - ASX: BLT) is pleased to announce that clinical data on its Phase I/IIa study of TT-034 for hepatitis C will be presented in the 'late-breaking poster' session at The Liver Meeting® 2015, the 66th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) being held in San Francisco on November 13-17, 2015. The abstract, which has been published on the conference website, details interim results from patients in the first three cohorts in Benitec's Phase I/IIa study of TT-034, a DNA-directed RNA interference agent (ddRNAi). The primary endpoint that this study is monitoring is safety of this first-in-man gene therapy-based gene silencing drug.

Social

About Benitec Biopharma Ltd

Benitec Biopharma Limited (Benitec) is an Australia-based company engaged in progressing its programs through the clinic, the commercialization of the Company's intellectual property (IP), development of its therapeutic pipeline and pre-clinical programs, funding, and protection and building the IP estate. The Company has a pipeline of in-house and partnered therapeutic programs based on its gene-silencing technology, deoxyribonucleic acid (DNA)-directed ribonucleic acid (RNA) interference (ddRNAi). It is engaged in developing treatments for chronic human conditions, such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, it has licensed its ddRNAi technology to other biopharmaceutical companies, including human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), retinitis pigmentosa and Huntington's disease.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BNTC
  • CUSIP:
Key Metrics:
  • Previous Close: $1.73
  • 50 Day Moving Average: $1.38
  • 200 Day Moving Average: $2.06
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $12.67M
  • Current Year EPS Consensus Estimate: $-1.13 EPS
  • Next Year EPS Consensus Estimate: $-2.77 EPS
Additional Links:
Benitec Biopharma Ltd (NASDAQ:BNTC) Chart for Wednesday, July, 27, 2016